Markedly prolonged disease course, with breakthrough seizures, in a glioma with an isolated IDH1 mutation is a research paper published in Neuro-Oncology Advances (2022). On theSindex it has a DataRank of 0.165. It has been cited 2 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.165
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Institutes of Health
Grant: R01NS102669
National Institutes of Health
Grant: R01NS117104
National Institutes of Health
Grant: R01NS118039
Northwestern SPORE in Brain Cancer
Grant: P50CA221747
National Institutes of Health
Grant: 5P50CA221747-02
SPORE for Translational Approaches to Brain Cancer
National Institutes of Health
Grant: 5R01NS102669-02
Tissue Factor as a Key Determinant of IDH1 Mutant versus IDH1 Wild-type Glioma Thrombosis and Malignancy
National Institutes of Health
Grant: 5R01NS118039-05
Targeting IDH mutations to improve seizure control in glioma patients
National Institutes of Health
Grant: 1R01NS117104-01
Interaction between Tissue Factor, Junctional Adhesion Molecule-A, and Integrin B1 to drive self-renewal in glioblastoma
Lou and Jean Malnati Brain Tumor Institute
FWCI
0.27
Citation Percentile
0.5%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals